ArticleOncotarget2016
Metformin use and cervical cancer risk in female patients with type 2 diabetes.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Knowledge mapping of metformin use on cancers: a bibliometric analysis (2013-2023).Frontiers in pharmacology · 2024Pooled it
- Association Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer.Frontiers in oncology · 2022Pooled it
- Pleiotropic Effects of Metformin on the Chemotherapy Response of HPV-Positive Cancer Cells.Journal of medical virology · 2025Article
- Synergistic impact of dysglycemia and HPV on cervical cancer risk: a potential mediating role of Ki-67.Frontiers in endocrinology · 2025Article
- Tissue-resident immune cells in cervical cancer: emerging roles and therapeutic implications.Frontiers in immunology · 2025Review
- Cervical carcinoma and diabetes mellitus among women in Southern India.Przeglad menopauzalny = Menopause review · 2024Article
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines.BMC cancer · 2024Article
- The Relationship between Metformin Consumption and Cancer Risk: An Updated Umbrella Review of Systematic Reviews and Meta-Analyses.International journal of preventive medicine · 2023Review
- Metformin and Cervical Cancer Risk in Patients with Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea.Endocrinology and metabolism (Seoul, Korea) · 2022Article
- Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus.Biomolecules · 2021Observational
- The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature.Biomolecules · 2021Review
- Impact of metformin on survival outcome in ovarian cancer: a nationwide population-based cohort study.Journal of gynecologic oncology · 2021Article
- Increasing risk of diabetes mellitus in postmenopausal women with newly diagnosed primary breast cancer.Journal of diabetes investigation · 2020Article
- Metformin and Biliary Tract Cancer in Patients With Type 2 Diabetes.Frontiers in oncology · 2020Article
- Metformin causes cancer cell death through downregulation of p53-dependent differentiated embryo chondrocyte 1.Journal of biomedical science · 2018Article
- Anti-Diabetic Drugs: Cure or Risk Factors for Cancer?Pathology oncology research : POR · 2018Review
- Sitagliptin and oral cancer risk in type 2 diabetes patients.Oncotarget · 2017Article
- Association of Metformin Use and Survival Outcome in Women With Cervical Cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2017Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated whether metformin may affect the risk of cervical cancer. The reimbursement databases of the Taiwan's National Health Insurance were used. Female patients with type 2 diabetes at an onset age of 25-74 years during 1999-2005 and newly treated with metformin (n=132971, "ever users of metformin") or other antidiabetic drugs (n=6940, "never users of metformin") were followed for at least 6 months until December 31, 2011. The treatment effect of metformin (for ever versus never users, and for tertiles of cumulative duration of therapy) was estimated by Cox regression incorporated with the inverse probability of treatment weighting using propensity score. Analyses were also conducted in a 1:1 matched pair cohort based on 8 digits of propensity score. Results showed that the respective numbers of incident cervical cancer in ever users and never users were 438 (0.33%) and 38 (0.55%), with respective incidences of 68.29 and 121.38 per 100,000 person-years. The overall hazard ratio suggested a significantly lower risk in metformin users (0.558, 95% confidence intervals: 0.401-0.778). In tertile analyses, the hazard ratios (95% confidence intervals) for the first (<23.0 months), second (23.0-47.9 months) and third (>47.9 months) tertile of cumulative duration were 1.272 (0.904-1.790), 0.523 (0.366-0.747) and 0.109 (0.070-0.172), respectively. Findings were supported by the analyses in the matched cohort. In conclusion, metformin may significantly reduce the risk of cervical cancer, especially when the cumulative duration is more than 2 years.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.